Table 3

Distribution of Saudi MS patients according to mRS (N=207).

VariablesmRSP-value
No disabilityMildSevereTotal
n (%)
Gender
 Male38 (31.7)16 (30.8)10 (28.6)64 (30.9)0.94
 Female82 (68.3)36 (69.2)25 (71.4)143 (69.1)
Smoking
 Yes26 (21.7)11 (21.2)1 (2.9)38 (18.4)0.34
 No91 (75.8)38 (73.1)33 (94.3)162 (78.3)
 Quit3 (2.5)3 (5.8)1 (2.9)7 (3.4)
Attacks last year
 Yes42 (35)23 (44.2)14 (40.0)79 (38.2)0.506
 No78 (65)29 (55.8)21 (60.0)128 (61.8)
Delayed diagnosis
 Yes25 (20.8)19 (36.5)14 (40.0)58 (28)0.021
 No95 (79.2)33 (63.5)21 (60.0)149 (72)
Medication use
 Yes95 (79.2)45 (86.5)19 (54.3)159 (76.8)0.003
 No25 (20.8)7 (13.5)16 (45.7)48 (23.2)
Compliance
 Compliant78 (82.1)33 (73.3)16 (84.2)127 (79.9)0.67
 Moderate8 (8.4)7 (15.6)1 (5.3)16 (10.1)
 Not compliant9 (9.5)5 (11.1)2 (10.5)16 (10.1)
Current medication
 Interferon beta-1a (Avonex)9 (9.5)4 (8.9)0 (0)13 (8.2)0.721
 Glatiramer acetate1 (1.1)0 (0)0 (0)1 (0.6)
 Interferon beta-1a (Rebif)41 (43.2)15 (33.3)7 (36.8)63 (39.6)
 Teriflunomide7 (7.4)3 (6.7)2 (10.5)12 (7.5)
 Fingolimod28 (29.5)13 (28.9)4 (21.1)45 (28.3)
 Dimethyl fumarate0 (0)3 (6.7)2 (10.5)5 (3.1)
 Alemtuzumab1 (1.1)2 (4.4)0 (0)3 (1.9)
 Natalizumab7 (7.4)5 (11.1)4 (21.1)16 (10.1)
 Daclizumab1 (1.1)0 (0)0 (0)1 (0.6)
  • mRS - modified rankin score